Relevance. Cutaneous manifestations of dermatoses at the open areas of the body significantly decrease the quality of life of patients. Thus, 81% of patients are embarrassed by their appearance, 75% of patients feel discomfort due to unattractive appearance, and depression symptoms are observed in 54%. The choice of drug treatment of facial dermatoses is very limited both in possible application and time. For practicing dermatologists, it is important to have in their repertoire some drug product that solves the problems of patients with rash located on the face. Objective. The study is aimed at assessing the clinical efficacy, safety and tolerability profile of the complex topical corticosteroid composed of methylprednisolone aceponate 0.1% + urea 2% (Komfoderm M2 cream) in routine practice in treatment of patients with steroid-sensitive facial dermatoses. Material and methods. To address this goal, we carried out 8 week-long open observational study, which involved 52 patients with steroid-sensitive facial dermatoses. The effectiveness of the therapy was assessed based of the detailed description of dermatological status and dermatological index of the quality of life before and after treatment. Results. Therapy with methylprednisolone aceponate 0.1% + urea 2% (Komfoderm M2 cream) demonstrated excellent clinical efficacy in 47 (90.4%) patients, good — in 4 (7.7%) patients, satisfactory — in 1 (1.9%) patients, unsatisfactory — in none of the patients. Tolerability of methylprednisolone aceponate 0.1% + urea 2% cream (Komfoderm M2) was excellent in 51 (98.1%) patients; good tolerability of the drug was reported in 1.9% (1 patient). No serious side effects were registered in this study. Conclusions. Topical treatment with methylprednisolone aceponate 0.1% + urea 2% cream (KomfodermM2) in patients with steroid-sensitive facial dermatoses is highly effective and safe.